PHARMACOGENOMICS STUDIES OF HUMAN HYPERTENSION

高血压(HTN)是一种多因素的特征，控制老年人血压(BP)的药物方法尚未奏效。因此，大多数患有HTN的美国人无法控制他们的BP。在比较不同的降压药物治疗方面存在着研究差距。这项拟议的研究将侧重于交感神经系统在HTN中所起作用的遗传易感性，作为GenHAT(高血压相关遗传学治疗)研究的一部分。这项研究的主要目的是确定多个HTN易感基因在α-受体阻滞剂对BP反应的个体间差异中的作用。这项研究将是一个试验性的实验室设计。可用于分析的样本量为9,081名患者，他们被随机分配到a受体阻滞剂多沙唑嗪。本课程将探讨治疗与基因之间的相互作用。据推测，对多沙唑嗪的反应将因特定的高血压变种而不同。对遗传学和BP药物治疗的关系的研究可能会指导未来针对患者HTN的病理进行的干预，从而更有效地控制BP。

Hypertension (HTN) is a multifactoral trait, and pharmacological methods to control blood pressure (BP) in older adults have not been effective. As a result, the majority of Americans with HTN do not have their BP under control. A research gap exists in comparing the different antihypertensive pharmacological treatments with each other. The proposed study will focus on the genetic susceptibility of the sympathetic nervous system's role in HTN as part of the GenHAT (Genetics of Hypertension Associated Treatment) study. The primary specific aim for this study is to determine the role of multiple HTN susceptibility genes in interindividual variation in BP response to alpha-blockers. The study will be an experimental laboratory design. The sample size available for analysis is 9,081 patients that were randomly assigned to the a blocker doxazosin. Treatment-genotype interactions will be explored. It is hypothesized that the response to doxazosin will differ with selected hypertensive variants. A study on the relation of genetics and BP pharmacological treatment may direct future intervention that is specific for the pathology of the patient's HTN and, therefore, more effective at controlling BP.